NCT06345755View on ClinicalTrials.gov

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

April 17, 2024

Primary Completion Date

January 27, 2025

Study Completion Date

June 13, 2025

Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
DRUG

VX-407

Solution or Suspension for oral administration.

DRUG

Placebo

Solution or Suspension for oral administration.

DRUG

Midazolam

Syrup for oral administration.

DRUG

VX-407

Suspension or Tablets for oral administration.

Trial Locations (2)

66219

ICON Lenexa, Lenexa

Unknown

Altasciences Montreal, Montreal

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT06345755 - A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants | Biotech Hunter | Biotech Hunter